RAF1 and breast cancer: Current FDA-approved RAS/RAF/MEK/ERK-targeted therapies for BC (Table 2) include HER2 antibodies such as trastuzumab, pertuzumab, and margetuximab, as well as small-molecule tyrosine kinase inhibitors (TKIs) like lapatinib, neratinib, and tucatinib [150].